Jidinum (Sitagliptin)

Sitagliptin works by selectively inhibiting the enzyme dipeptidyl peptidase‑4 (DPP‑4). This inhibition raises levels of the incretin hormones GLP‑1 and GIP, which increase insulin secretion and reduce glucagon release in a glucose‑dependent manner, helping to lower blood sugar.

The appropriate dose of Jidinum is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and response to therapy. Patients should follow the dosage instructions provided by their prescriber and pharmacist.

Safety of sitagliptin in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To order Jidinum, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Jidinum (sitagliptin) belongs to the DPP‑4 inhibitor class, offering glucose‑dependent insulin release with a low risk of hypoglycaemia compared with sulfonylureas. Unlike insulin, it is taken orally and does not require injection, making it a convenient option for many patients.

Store Jidinum tablets at ambient temperature, below 25 °C, in the original packaging. Protect them from moisture, direct sunlight and excessive heat. Keep the product out of reach of children and do not use after the expiry date.

Jidinum is taken orally, usually once daily, with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

The most serious adverse events reported with sitagliptin include pancreatitis, severe allergic reactions such as angioedema or anaphylaxis, and rare skin conditions like bullous pemphigoid. Patients should seek immediate medical attention if they experience severe abdominal pain, rash, or swelling.

Jidinum should be avoided in patients with a known hypersensitivity to sitagliptin or any component of the formulation. Caution is also advised for individuals with severe renal impairment, active pancreatitis, or those for whom the benefits of therapy do not outweigh potential risks.